Key result
Dexrazoxane is the only known agent associated with less cardiac dysfunction without reducing the oncologic efficacy of the anthracycline doxorubicin in children.
Population
Childhood cancer survivors treated with anthracyclines
Design
Review
Authors
Loading...
Supports dexrazoxane consideration in children on doxorubicin; extends evidence but leaves open need for prospective trials.
Dexrazoxane is highlighted as the primary cardioprotective agent to mitigate anthracycline-induced cardiotoxicity in childhood cancer survivors without compromising oncologic efficacy.
Harake et al. (2012) conducted a review in Childhood cancer survivors at risk of cardiotoxicity. Dexrazoxane was evaluated. Dexrazoxane is the only known agent associated with less cardiac dysfunction without reducing the oncologic efficacy of the anthracycline doxorubicin in children.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: